Eli Lilly and Co. (NYSE:LLY)‘s stock had its “overweight” rating reissued by research analysts at JPMorgan Chase & Co. in a research report issued to clients and investors on Saturday. They currently have a $384.00 price target on the stock. JPMorgan Chase & Co.’s price objective suggests a potential upside of 455.56% from the stock’s current price.
A number of other research analysts have also recently issued reports on LLY. Citigroup Inc. reaffirmed a “buy” rating on shares of Eli Lilly and in a report on Tuesday, November 8th. Zacks Investment Research raised Eli Lilly and from a “hold” rating to a “buy” rating and set a $93.00 price objective for the company in a report on Friday, July 29th. Leerink Swann reissued an “outperform” rating and set a $105.00 price objective on shares of Eli Lilly and in a report on Saturday, August 13th. Morgan Stanley set a $73.00 price objective on Eli Lilly and and gave the stock a “hold” rating in a report on Thursday. Finally, BMO Capital Markets reissued an “outperform” rating and set a $94.00 price objective on shares of Eli Lilly and in a report on Tuesday, September 27th. Four analysts have rated the stock with a hold rating and seventeen have issued a buy rating to the company’s stock. Eli Lilly and presently has a consensus rating of “Buy” and an average target price of $108.95.
Shares of Eli Lilly and (NYSE:LLY) opened at 69.12 on Friday. Eli Lilly and has a 52-week low of $64.18 and a 52-week high of $88.16. The stock has a market capitalization of $73.11 billion, a price-to-earnings ratio of 30.07 and a beta of 0.28. The stock has a 50 day moving average of $76.69 and a 200-day moving average of $77.92.
Eli Lilly and (NYSE:LLY) last released its quarterly earnings results on Tuesday, October 25th. The company reported $0.88 earnings per share (EPS) for the quarter, missing the Zacks’ consensus estimate of $0.96 by $0.08. Eli Lilly and had a net margin of 11.73% and a return on equity of 23.71%. The business earned $5.19 billion during the quarter, compared to the consensus estimate of $4.23 billion. During the same period in the prior year, the firm earned $0.89 earnings per share. The business’s quarterly revenue was up 4.7% compared to the same quarter last year. On average, equities research analysts predict that Eli Lilly and will post $3.55 EPS for the current fiscal year.
The company also recently announced a quarterly dividend, which will be paid on Friday, December 9th. Shareholders of record on Tuesday, November 15th will be paid a $0.51 dividend. This represents a $2.04 annualized dividend and a yield of 2.95%. The ex-dividend date is Thursday, November 10th. Eli Lilly and’s payout ratio is 88.70%.
In other Eli Lilly and news, insider Maria A. Crowe sold 2,248 shares of the business’s stock in a transaction that occurred on Wednesday, October 5th. The stock was sold at an average price of $81.37, for a total value of $182,919.76. Following the sale, the insider now owns 94,319 shares in the company, valued at approximately $7,674,737.03. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink. 0.20% of the stock is owned by company insiders.
Large investors have recently added to or reduced their stakes in the stock. BlueMountain Capital Management LLC purchased a new stake in Eli Lilly and during the first quarter valued at approximately $482,000. Iowa State Bank purchased a new stake in Eli Lilly and during the second quarter valued at approximately $104,000. Stock Yards Bank & Trust Co. boosted its stake in Eli Lilly and by 11.0% in the second quarter. Stock Yards Bank & Trust Co. now owns 22,976 shares of the company’s stock valued at $1,810,000 after buying an additional 2,283 shares during the last quarter. New England Research & Management Inc. purchased a new stake in Eli Lilly and during the second quarter valued at approximately $583,000. Finally, Park National Corp OH boosted its stake in Eli Lilly and by 12.7% in the second quarter. Park National Corp OH now owns 100,178 shares of the company’s stock valued at $7,889,000 after buying an additional 11,283 shares during the last quarter. Hedge funds and other institutional investors own 75.11% of the company’s stock.
About Eli Lilly and